Skip to main content
GeoVax Labs, Inc. logo

GeoVax Labs, Inc. — Investor Relations & Filings

Ticker · GOVX ISIN · US3736786068 LEI · 549300KXK8Z4UZ4J7S86 US Professional, scientific and technical activities
Open in API
Filings indexed 1,074 across all filing types
Latest filing 2026-06-03 Regulatory Filings
Country US United States of America
Listing US GOVX

About GeoVax Labs, Inc.

https://www.geovax.com/

GeoVax Labs, Inc. is a clinical-stage biotechnology company that develops human vaccines and immunotherapies for infectious diseases and cancer using proprietary platforms. The company's lead oncology program is Gedeptin®, a therapy for advanced head and neck cancers which has completed enrollment in a Phase 1/2 clinical trial. Its primary infectious disease candidate is GEO-CM04S1, a next-generation COVID-19 vaccine being evaluated in Phase 2 clinical trials for high-risk, immunocompromised populations and as a heterologous booster. GeoVax's development pipeline also includes research programs for preventive vaccines against Mpox, smallpox, hemorrhagic fever viruses such as Ebola and Marburg, malaria, and Zika virus, alongside therapies for various solid tumors.

Recent filings

Filing Released Lang Actions
GeoVax CEO Highlights Renewed Strategic Interest in Vaccine Platforms and Infectious Disease Innovation
Regulatory Filings Classification · 15% confidence The document is a corporate press release distributed via EQS News, providing commentary from the CEO on industry trends and strategic focus. It contains no financial results, meeting materials, voting results, or regulatory form filings. It does not present financial statements, governance details, or transaction notices. Therefore, it is best classified as a general regulatory/press announcement under RNS.
2026-06-03 English
GeoVax CEO Welcomes FIFA World Cup 2026 While Addressing Biothreat Readiness
Regulatory Filings Classification · 16% confidence The document is a corporate press release via EQS News announcing the CEO’s comments on public health readiness for FIFA World Cup 2026. It contains no financial results, governance changes, share transactions, or formal regulatory report attachments, nor is it an investor presentation or report publication notice. It serves as general corporate news, fitting the fallback category for miscellaneous regulatory announcements.
2026-06-01 English
Registration Now Open for Tribe Public CEO Presentation and Q&A Webinar Event
Regulatory Filings Classification · 80% confidence The document is a corporate press release announcing registration for a CEO webinar event. It contains an investor‐oriented marketing announcement without any substantive financial statements, voting details, board changes, or regulatory filings. This fits the “Regulatory Filings (RNS)” category as a general corporate news announcement, not an actual financial report or presentation material.
2026-05-27 English
GeoVax Accelerates Focus on GEO-MVA Commercialization and Advancement of Oncology Program Gedeptin(R)
Regulatory Filings Classification · 82% confidence The document is a corporate press release providing strategic program updates for GeoVax rather than presenting financial results, governance changes, or vote outcomes. It does not contain substantive financial statements, regulatory filings, or detailed investor materials. It functions as a general corporate/business announcement disseminated via EQS News. Therefore, it falls under the broad “Regulatory Filings” (RNS) category as a general announcement that does not fit more specific categories.
2026-05-26 English
FORM S-1
Regulatory Filings Classification · 85% confidence The document is a preliminary prospectus filed as an SEC Form S-1 registration statement for the resale of shares, including detailed offering terms, risk factors, MD&A, business overview, plan of distribution, etc. It does not contain periodic financial statements as in an Annual or Interim Report, nor is it an earnings release or proxy statement. It is primarily a compliance document filed with the SEC to register securities for sale. Therefore it fits best under the general “Regulatory Filings” category (RNS).
2026-05-26 English
GeoVax Comments on Escalating Bundibugyo Ebola Outbreak and Growing Need for Flexible Biodefense Vaccine Platforms
Regulatory Filings Classification · 95% confidence The document is a corporate news announcement from GeoVax, Inc. discussing the escalating Bundibugyo Ebola outbreak and the company's vaccine development programs. It contains no financial statements, no regulatory filings, no voting results, no management changes, no earnings data, and no detailed financial or operational reports. The content is primarily a press release or corporate news update about the company's scientific and strategic positioning related to infectious disease preparedness and vaccine development. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or any other financial or regulatory filing. Given the nature and content, this is best classified as a Regulatory Filing (RNS) as a general corporate announcement that does not fit other specific categories.
2026-05-20 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.